475 related articles for article (PubMed ID: 25914523)
1. Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3.
Pirillo A; Catapano AL
Drug Des Devel Ther; 2015; 9():2129-37. PubMed ID: 25914523
[TBL] [Abstract][Full Text] [Related]
2. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
3. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia.
Pirillo A; Catapano AL
Int J Cardiol; 2013 Dec; 170(2 Suppl 1):S16-20. PubMed ID: 23856442
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.
Tatsuno I
Expert Rev Cardiovasc Ther; 2014 Nov; 12(11):1261-8. PubMed ID: 25319059
[TBL] [Abstract][Full Text] [Related]
6. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson MH; Johnson J; Rooney MW; Kyle ML; Kling DF
J Clin Lipidol; 2012; 6(6):573-84. PubMed ID: 23312053
[TBL] [Abstract][Full Text] [Related]
7. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of hypertriglyceridemia with omega-3 fatty acids].
Miyoshi T; Ito H
Nihon Rinsho; 2013 Sep; 71(9):1650-4. PubMed ID: 24205729
[TBL] [Abstract][Full Text] [Related]
9. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Offman E; Marenco T; Ferber S; Johnson J; Kling D; Curcio D; Davidson M
Vasc Health Risk Manag; 2013; 9():563-73. PubMed ID: 24124374
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
11. ω-3 carboxylic acids for hypertriglyceridemia.
Roth EM
Expert Opin Pharmacother; 2015 Jan; 16(1):123-33. PubMed ID: 25480558
[TBL] [Abstract][Full Text] [Related]
12. History and future of omega-3 fatty acids in cardiovascular disease.
Sperling LS; Nelson JR
Curr Med Res Opin; 2016; 32(2):301-11. PubMed ID: 26566071
[TBL] [Abstract][Full Text] [Related]
13. A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies
Lopez-Toledano MA; Thorsteinsson T; Daak A; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
Clin Ther; 2017 Mar; 39(3):581-591. PubMed ID: 28189364
[TBL] [Abstract][Full Text] [Related]
14. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
Harris WS; Dayspring TD; Moran TJ
Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
[TBL] [Abstract][Full Text] [Related]
17. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
Ito MK
Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
[TBL] [Abstract][Full Text] [Related]
18. A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States.
Lapointe JF; Harvey L; Aziz S; Jordan H; Hegele RA; Lemieux P
Clin Ther; 2019 Mar; 41(3):426-444. PubMed ID: 30799231
[TBL] [Abstract][Full Text] [Related]
19. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
20. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
